MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
In plain words A Phase 2 study of MOTS-c in people 18 to 65, run by Hudson Biotech. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Prediabetes; Insulin Resistance; Overweight/Obesity.
- Age 18 to 65 years at the time of consent.
- Body mass index (BMI) 27.0 to 40.0 kg/m\^2.
- Prediabetes documented at screening by any of the following: (a) HbA1c 5.7% to 6.4%; (b) fasting plasma glucose 100 to 125 mg/dL; or (c) 2-hour plasma glucose 140 to 199 mg/dL during a 75 g OGTT.
- Stable body weight (less than 5% change) for at least 3 months prior to screening.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
MOTS-c (MDP); Placebo; Route Subcutaneous injection; Regimen
Registered summary
This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity. Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.
Where, as registered
No US site; China (1).